

Effectivity of intravesical thermo-chemotherapy prophylaxis for patients with high recurrence and progression risk for non-muscle invasive bladder cancer

Ali Serdar Gözen¹, Paolo Umari², Walter Scheitlin¹, Fuat Ernis Su³, Yigit Akin⁴, **Jens Rassweiler**¹

¹ Department of Urology, SLK-Kliniken, University of Heidelberg, Heilbronn, Germany;

² Department of Urology, Cattinara Hospital, University of Trieste, Italy;

³ Department of Urology, Kanuni Sultan Süleyman Education and Research Hospital, Istanbul, Turkey;

⁴ Department of Urology, Harran University School of Medicine, Sanliurfa, Turkey.

Summary

Background&Aim: High grade non-muscle invasive bladder cancer (NMIBC) is common in urological practice. Most of these cancers are or become refractory to intravesical immunotherapy and chemotherapy. Here we evaluated the efficacy of combined local bladder hyperthermia and intravesical mitomycin-C (MMC) instillation in patients with high-risk recurrent NMIBC.

Materials and methods: Between February 2014 and December 2015, 18 patients with high risk NMIBC were enrolled. Patients were treated in an outpatient basis with 6 weekly induction sessions followed by monthly maintenance sessions with intravesical MMC in local hyperthermia with bladder wall thermo-chemotherapy (BWT) system (PelvixTT system, Elmedical Ltd., Hod Hasharon, Israel). The follow-up regimen included cystoscopy after the induction cycle and thereafter with regular intervals. Time to disease recurrence was defined as time from the first intravesical treatment to endoscopic or histological documentation of a new bladder tumour. Adverse events were recorded according to CTC 4.0 (Common Toxicity Criteria) score system.

Results: Mean age was 72 (32-87) years. 10 patients had multifocal disease, 9 had CIS, 6 had recurrent disease and 2 had highly recurrent disease (> 3 recurrences in a 24 months period). 6 patients underwent previous intravesical chemotherapy with MMC. The average number of maintenance sessions per patient was 7.6. After a mean follow-up of 433 days, 15 patients (83.3%) were recurrence-free. 3 patients had tumour recurrence after a mean period of 248 days without progression. Side effects were limited to grade 1 in 2 patients and grade 2 in 1 patient.

Conclusions: BWT seems to be feasible and safe in high grade NMIBC. More studies are needed to identify the subgroup of patients who may benefit more from this treatment.

KEY WORDS: Bladder cancer; Mitomycin-C; Regional perfusion cancer chemotherapy.

Submitted 12 August 2016; Accepted 11 January 2017

INTRODUCTION

The non-muscle invasive bladder cancer (NMIBC) is the 4th most common cancer in men and 12th in women with a great impact on health care system in Europe (1). Nearly 80% of the patients with bladder cancer present with non-

muscle invasive disease at the diagnosis (2). The mean characteristics of this cancer are high recurrence rates after transurethral resection and high risk of progression to muscle invasive disease (3). Although, intravesical chemotherapy and immunotherapy can significantly decrease the recurrence and progression rates, they still represent the main challenge in this field and more effective therapies are needed (4). Particularly challenging is the treatment of patients with high-risk tumours according to the *European Organization for Research and Treatment of Cancer* (EORTC) scoring system and those who are refractory to intravesical *Bacillus Calmette-Guérin* (BCG) instillation (1). Moreover, there has been a shortage of BCG in Europe.

Many approaches have been used to enhance the antitumor effects of intravesical chemotherapy (5). Several studies have shown promising results combining intravesical mitomycin-C (MMC) with hyperthermia. It was demonstrated that hyperthermia of the bladder wall improves MMC penetration into the deep bladder wall and can offer anticancer advantages over chemotherapy instillation alone (6).

The aim of this study was to evaluate the efficacy of combined intravesical MMC instillation and bladder hyperthermia in a selected group of patients with high-risk recurrent NMIBC in whom radical surgery was not an option or BCG treatment was contraindicated.

MATERIALS AND METHODS

This was a retrospective evaluation of prospectively collected data. The Ethics Committee of our institution approved the present study. All patients read, understood, and signed the consents forms. All procedures performed were in accordance with the Helsinki declaration or comparable ethical standards.

Patient and data collection

Between, February 2014 and December 2015, 24 patients with high risk NMIBC underwent adjuvant thermo-chemotherapy with MMC at our Department. The exclusion criteria were patients with muscle invasive

No conflict of interest declared.

bladder cancer, low risk bladder cancer, histology different than transitional, tumours involving the urethra or upper urinary tract, large bladder diverticulum (> 1 cm), patients underwent previous partial cystectomy and impossibility to undergo catheterisation with a 20 French catheter. 18 patients were eligible for the analysis and were included in the study.

The other 6 patients did not meet the inclusion criteria, because 2 of them had incomplete data, 1 had muscle invasive disease, 1 had squamous tumour at histology, 1 had multiple tumours involving the urethra and 1 withdrew treatment at 3rd instillation because of his personal decision. We used tumour node metastasis (TNM) classification of 2009 for defining levels of NMIBC in the study (7).

Treatment

Patients were treated on an outpatient basis with 6 weekly induction sessions followed by monthly maintenance sessions of intravesical MMC and bladder thermo-chemotherapy (BWT). The maintenance treatment was prosecuted for up to 1 year and patients with no recurrences underwent to an additional maintenance cycle every 3 months thereafter.

The Unithermia System (Pelvix TT system, Elmedical Ltd., Hod Hasharon, Israel) was used to heat the bladder wall, in all patients. This system is composed of a compact console with a peristaltic pump and a heat exchanger that delivers intravesical MMC through a 3-way silicon 20 French catheter. It allows to obtain a uniform hyperthermia all over the bladder by continuous flow of the heated MMC solution. According to previous studies, patients received 80 mg of MMC in 50 ml 0.9% saline, heated at 45°C in continuous circulation for 50 minutes (8) (Figure 1).

Figure 1.

The Unithermia System (Pelvix TT system, Elmedical Ltd., Hod Hasharon, Israel) used to heat the bladder wall. It is composed from a compact console with a peristaltic pump and a heat exchanger that delivers intravesical chemotherapy through a 3-way silicon 20 French catheter. The uniform hyperthermia at 45°C of 80 mg MMC in 50 ml 0.9% saline solution is maintained for 50 minutes by the continuous flow.



Follow-up

The follow-up regimen included cystoscopy after the induction cycle and after that every 3 months for a period of 2 years. Thereafter the follow-up was conducted every 6 months. All lesions that were detected by cystoscopy during follow-up underwent biopsy. The recurrence was evaluated by histological examination. Patients without tumour in the bladder and positive cytology underwent bladder mapping to exclude the presence of a carcinoma in-situ (CIS). The transitional cell carcinoma of the upper urinary tract was also rolled out with appropriate imaging in these cases. Time to disease recurrence was defined as the time from the first intravesical treatment to endoscopic or histological documentation of a new bladder tumour. Adverse events were recorded regarding the Common Toxicity Criteria (CTC) 4.0 score system (9).

RESULTS

Description

The mean age was 72 years (range 32-87). There were 16 male and 2 female patients. In total, 10 patients had multifocal disease, 9 had CIS, 7 had recurrent diseases and 2 of them had a highly recurrent disease (> 3 recurrences in a 24 months period). Both of last 2 patients had also a concurrent T1G3 disease. Stage before starting the BWT treatment was Ta in 5 patients, and T1 in 12 patients and all the patients had high grade (G2-3) disease. 6 patients have undergone previous intravesical therapy with MMC. The average number of maintenance sessions per patient was 7.6. All patients conducted the treatment during the induction and maintenance period with no significant side effects due to MMC and no physical complaints due to bladder hyperthermia. Table 1 summarizes patients' characteristics.

Table 1.

Patients characteristics.

Patients characteristics	
Number of patients (total)	24
Number of patients (included)	18
Age	
mean (range)	72 (32-87)
Gender	
male	16
female	2
Recurrence history	
recurrent	7
highly recurrent	2
Number of tumours before BWT	
unifocal	8
multifocal	10
Tumor stage prior BWT	
Ta	5
T1	12
CIS	9
Prior intravesical therapy	
BCG	0
MMC	6
none	12

BCG: Bacillus Calmette-Guérin; BWT: bladder wall thermo-chemotherapy; MMC: Mitomycin C.

Treatment results

After a mean follow-up of 433 days, 15 patients (83.3%) were recurrence-free. Besides, no patient had recurrence at the first cystoscopy after the induction cycle. 3 patients had tumour recurrence after a mean period of 248 days (range 191-339 days). However there was no disease progression, in fact staging and grading of these patients prior the treatment and at the time of recurrence were: T1G3+CIS, TaG2, CIS and T1G3, TaG1, CIS respectively. 2 of them had multifocal disease recurrence. None among the 2 patients with highly recurrent disease relapsed during a mean follow-up of 655 days. These results are summarized in Table 2.

Side effects

Side effects according to CTC 4.0 were limited to grade 1 in 2 patients (skin allergy and haematuria) and grade 2 in 1 patient (pain and bladder spasm during induction treatment sessions treated with intravesical oxybutynin). Grade 1 complications were treated with oral analgesics and antispasmodics respectively.

Table 2.

Review of the current series results.

Parameters	
Mean follow-up (days)	433
Recurrence free rate	15/18 (83,3%)
Mean recurrence time (days)	248 (191-339)
Disease progression	0/18 (0%)
Side effects (According to CTC)	
grade 1	2 (11,1%)
grade 2	1 (5,6%)
grade 3	0 (0%)
grade 4	0 (0%)
grade 5	0 (0%)

CTC: Common toxicity criteria.

DISCUSSION

The NMIBC is characterised by a high recurrence rate (30-85%) after primary transurethral resection of the tumour (2). Thus, intravesical immunotherapy with BCG or MMC is used for preventing recurrence (1). It is well known that BCG can significantly reduce the disease progression and recurrence rate but at the same time can also produce serious side effects such as voiding problems, urinary infection, haematuria up to miliary tuberculosis (10, 11). In these cases only MMC can be used as intravesical therapy (12). On the other hand, since more than hundred years ago, many experiments have shown that cancer cells are more susceptible to hyperthermia than normal healthy cells (13). Local hyperthermia has a therapeutic potential for the treatment of many solid tumours, especially if used in combination with other treatments, such as radiation (*Radio hyperthermia*) and chemotherapy (*Chemo hyperthermia*) (14).

Lammers *et al.* reported a systematic review of 15 original articles and concluded that MMC+hyperthermia reduces the risk of NMIBC recurrence by 59% when compared to MMC alone despite a limited number of randomized tri-

als in current literature (15). The bladder is particularly suitable for the application of local hyperthermia because its wall could be heated by the irrigation of warm fluid (15). Until now, several chemotherapeutics in various dosages and different regimens (adjuvant and neo-adjuvant) have been used in association with hyperthermia (16). Intravesical MMC was recently used for preventing the recurrence and the progression of NMIBC (17). It was demonstrated, that MMC associated with hyperthermia could have promising effects on a well selected subgroup of patients (18). It has been shown that hyperthermia interferes with DNA, RNA and protein synthesis of cancer cells. Moreover intravesical MMC can inactivate cell repair mechanisms by increasing tumour cell apoptosis (19). For these reasons intravesical MMC associated with thermotherapy may be used as prophylaxis for recurrence and progression in high grade NMIBC.

Heating of the bladder can be achieved, by radiofrequency, by magnetic nanoparticles in magnetic field or by circulation of externally heated fluid into the bladder (19). The most used systems are the Synergo system (SB-TS 101 ± 1 System introduced by Colombo *R et al.* in 1996) and the more recently Unithermia system (20, 21). The former is based on direct irradiation of the bladder lumen by a 915-MHz intravesical microwave applicator and the latter comprises a console with a peristaltic pump and a heat exchanger that delivers intravesical chemotherapy through a 3-way silicon catheter (8). Another method was recently proposed and consists on regional hyperthermia therapy using an array of 70 to 120 MHz antennas that are positioned around the patient, resulting in high homogenous temperatures of the target organ (22). We used the Unithermia system in the current study because of its easy applicability.

In our study thermo-chemotherapy with MMC provided promising results with low recurrence rate and no disease progression in patients with high grade NMIBC at a medium-term follow-up period. The overall rate of side effects was low and the acceptance of the treatment by the patient was high.

The main limitation of the current study is the small number of patients and therefore the impossibility to perform an accurate statistical analysis. The favorable factors are the only inclusion of patient with a high risk disease according to EORTC classification in whom radical surgery was not an option or BCG treatment was contraindicated. Moreover all patients followed strictly the therapy plan and the follow-up schedule.

CONCLUSIONS

According to these data thermo-chemotherapy seems to be a feasible, safe and promising approach for prophylactic treatment in patients with high risk NMIBC. More studies are needed to identify the subgroup of patients who may benefit more from this treatment (ex. old patients with short life expectancy, those who are not candidates for anesthesia due to high comorbidities or not suited for BCG therapy, those who refuse radical surgery and prefer conservative treatment to keep the bladder in situ). These preliminary results encourage further studies to define the limits and prospects of this regimen.

REFERENCES

1. <http://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/> Accessed June.16.2016.
2. Aldousari S, Kassouf W. Update on the management of non-muscle invasive bladder cancer. *Can Urol Assoc J*. 2010; 4:56-64.
3. Van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. *Eur Urol*. 2009; 56:430-442.
4. Geijsen ED, de Reijke TM, Koning CC, et al. Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study. *J Urol*. 2015; 194:1202-1208.
5. Arends TJ, Falke J, Lammers RJ, et al. Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia. *World J Urol*. 2015; 33:1411-1417.
6. Maffezzini M, Campodonico F, Canepa G, et al. Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression. *Cancer Chemother Pharmacol* 2014; 73:925-930.
7. UICC International Union Against Cancer. In: Sobin Lh, Gospodariwicz M, Wittekind C, editors. 7th ed. Oxford: Wiley-Blackwell TNM classification of malignant tumours. 2009; p.262-265.
8. <http://www.elmedical-group.com/home/doc.aspx?mCatID=13636>. Accessed June.16.2016.
9. https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed June.16.2016.
10. Holz S, Sotorres Cabanillas JL, Legrand F, et al. Evaluation of adverse events caused by intravesical BCG instillations: Has the strain used a potential implication? *Prog Urol*. 2016; 26:73-78.
11. Rosati Y, Fabiani A, Taccari T, et al. Intravesical BCG therapy as cause of miliary pulmonary tuberculosis. *Urologia*. 2016; 82:49-53.
12. Porten SP, Leapman MS, Greene KL. Intravesical chemotherapy in non-muscle-invasive bladder cancer. *Indian J Urol*. 2015; 31:297- 303.
13. Edwards MJ. Apoptosis, the heat shock response, hyperthermia, birth defects, disease and cancer. Where are the common links? *Cell Stress Chaperones*. 1998; 3:213-220.
14. Hurwitz M, Stauffer P. Hyperthermia, radiation and chemotherapy: the role of heat in multidisciplinary cancer care. *Semin Oncol*. 2014; 41:714-729.
15. Lammers RJ, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. *Eur Urol*. 2011; 60:81-93.
16. Colombo R. Combined treatment with local thermo-chemotherapy for non muscle invasive bladder cancer. The present role in the light of acquired data and preliminary cumulative clinical experiences. *Arch Ital Urol Androl*. 2008; 80:149-156.
17. Milla P, Fiorito C, Soria F, et al. Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with mitomycin C in superficial transitional cell carcinoma patients. *Cancer Chemother Pharmacol*. 2014; 73:503-509.
18. Owusu RA, Abern MR, Inman BA. Hyperthermia as adjunct to intravesical chemotherapy for bladder cancer. *Biomed Res Int*. 2013; 262313.
19. Slater SE, Patel P, Viney R, et al. The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer. *Ann R Coll Surg Engl*. 2014; 96:415-419.
20. Kiss B, Schneider S, Thalmann GN, Roth B. Is thermo-chemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer? *Int J Urol*. 2015; 22:158-162.
21. Soria F, Milla P, Fiorito C, et al. Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I-II study. *World J Urol*. 2016; 34:189-195.
22. Geijsen ED, de Reijke TM, Koning CC, et al. Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study. *J Urol*. 2015; 194:1202-1208.

Correspondence

Ali Serdar Gözen, MD, FEBU. Associate Professor of Urology (Corresponding Author)
asgozen@yahoo.com

Walter Scheitlin, MD

Jens Rassweiler, MD
Department of Urology - SLK-Kliniken Heilbronn
Am Gesundbrunnen 20-26, D-74078 Heilbronn, Germany

Paolo Umari, MD
Department of Urology, Cattinara Hospital, University of Trieste
Trieste, Italy

Fuat Ernis Su, MD
Department of Urology, Kanuni Sultan Süleyman Education
and Research Hospital, Istanbul, Turkey

Yigit Akin, MD
Department of Urology, Harran University School of Medicine
Sanliurfa, Turkey